Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: fifteen-year results.
OBJECTIVE
To assess the long-term outcome of patients with lymphadenectomy-staged prostate cancer treated with external beam radiotherapy.


METHODS
A retrospective analysis was performed on all patients with prostate cancer who underwent staging pelvic lymphadenectomy before treatment with definitive radiotherapy from 1970 to February 1978. This included 71 patients who were evaluated for a minimum of fifteen years. No patients were lost to follow-up. Thirty-five patients were node negative and 36 were node positive.


RESULTS
Fifteen-year actuarial overall survival, cause-specific survival, and local control for the 20 patients with clinically organ-confined disease (T1b-T2 N0M0) was 40 percent, 75 percent, and 92 percent, respectively. The results for the 15 T3 N0M0 patients were 15 percent, 22 percent, and 60 percent. Patients with positive nodes did much worse, with rates of 5 percent, 6 percent, and 45 percent. Thirty-four patients received hormonal therapy at the time of first failure. No patient who was clinically free of disease at fifteen years had an elevated level of prostate-specific antigen (PSA).


CONCLUSIONS
Our data suggest excellent results in a cohort of patients (T1b-T2 N0M0) treated with primary radiotherapy who would be considered candidates for radical prostatectomy. Outcome is significantly worse in patients with T3 lesions and node-positive disease.
Lee
R J
RJ
Radiation Center, LDS Hospital, Salt Lake City, Utah.
Sause
W T
WT
D000206:Actuarial Analysis; D000368:Aged; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011882:Radiotherapy, High-Energy; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome